Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT

Oncol Rep. 2019 Dec;42(6):2716-2727. doi: 10.3892/or.2019.7347. Epub 2019 Oct 1.

Abstract

Acquired resistance to cisplatin (CDDP) in esophageal squamous cell carcinoma (ESCC) remains a major challenge in cancer therapy. Although progress has been made in identifying the mechanisms responsible for resistance to CDDP, the underlying mechanisms of resistance in ESCC are still not entirely understood. In the present study, a CDDP‑resistant ESCC cell line EC109/CDDP was established by culturing parental EC109 cells in increasing concentrations of CDDP, and it was demonstrated that MutY homolog (MUTYH), a critical base excision repair gene, was significantly downregulated in the resistant EC109/CDDP cells compared with that noted in the parental cells. Ectopic expression of MUTYH by transient transfection of pcDNA3.1‑MUTYH plasmid significantly enhanced the CDDP‑mediated inhibitory effect on resistant cell proliferation and induction of apoptosis, while silencing of MUTYH by transiently transfecting MUTYH‑targeted siRNA in parental cells led to decreased sensitivity to CDDP as demonstrated by MTT assay, suggesting the crucial involvement of MUTYH in CDDP resistance. Further experiments demonstrated that the CDDP‑resistant cells went through epithelial‑mesenchymal transition (EMT) driven by its master regulator Twist, and MUTYH overexpression significantly reduced the Twist expression level and reversed the phenotype of EMT as detected by western blot analysis and RT‑qPCR assays, suggesting that downregulation of MUTYH contributed to the Twist‑mediated EMT. Moreover, it was observed that the effect of MUTYH on Twist was also associated with its degradation in addition to transcription. MUTYH acted as a positive regulator of reactive oxygen species (ROS) that showed a low level in resistant cells via flow cytometry assay, as demonstrated by increased ROS production in response to MUTYH overexpression. Reduced ROS by using N‑acetylcysteine led to a decrease in proteasome activity and sequentially inhibited the degradation of Twist. In conclusion, the present data demonstrated that EMT activation mediated by MUTYH downregulation, by both enhancing Twist transcription and blocking its degradation, is one of the mechanisms for acquisition of CDDP resistance in ESCC.

MeSH terms

  • Acetylcysteine / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / adverse effects
  • Cisplatin / pharmacology
  • DNA Glycosylases / genetics*
  • Drug Resistance, Neoplasm / genetics*
  • Epithelial-Mesenchymal Transition / genetics
  • Esophageal Squamous Cell Carcinoma / drug therapy*
  • Esophageal Squamous Cell Carcinoma / genetics
  • Esophageal Squamous Cell Carcinoma / pathology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Nuclear Proteins / genetics*
  • Proteolysis / drug effects
  • RNA, Small Interfering / genetics
  • Reactive Oxygen Species / metabolism
  • Signal Transduction / drug effects
  • Twist-Related Protein 1 / genetics*

Substances

  • Nuclear Proteins
  • RNA, Small Interfering
  • Reactive Oxygen Species
  • TWIST1 protein, human
  • Twist-Related Protein 1
  • DNA Glycosylases
  • mutY adenine glycosylase
  • Cisplatin
  • Acetylcysteine